www.fdanews.com/articles/82007-nicox-topigen-sign-deal-on-respiratory-drug
NICOX, TOPIGEN SIGN DEAL ON RESPIRATORY DRUG
October 28, 2005
French biotechnology company NicOx said on Thursday it had signed an agreement giving Canadian-based Topigen the North American rights to develop and market its experimental NCX 1020 treatment for inflamed lungs. Under the statement NicOx would receive a 2 million euro ($2.4 million) upfront payment and up to 52.9 million euros in milestones and commercial success fees in addition to a share in future revenues, it said in a statement.